Abstract:Background: Programmed cell death ligand 1 (PD-L1) expression by immunohistochemistry (IHC) is a predictive factor for anti–PD-1/PD-L1 monoantibodies. However, intertumoral heterogeneity of PD-L1 expression and its accordance between resected tissue and biopsy tissue or cytological tumor samples remains controversial. Methods: A total of 72 patients who consecutively undergone primary lung cancer resection and were diagnosed as pulmonary adenosquamous carcinoma were included. PD-L1 expression level was assessed by IHC (PD-L1: Clone E1L3N; Cell Signaling #13684) in different histological component of both primary and lymph node tissues respectively. Results: With a 5% of cutoff, PD-L1 expression was 20.8%, 33.3% in adenomatous and squamous cell component respectively. When various cutoffs including 0.01, 0.05, 0.10 were used, the PD-L1 expression was discrepant in 26.4%, 19.4%, 12.5% cases respectively. With combination of the expression in tumor cells (TC) and tumor-infiltrated lymphocytes (TILs), discrepancies between two histological components were observed in 13.9%, 22.2%, 30.6% cases repectively. Of 38 lymphatic metastasis cases, there were 4 types of lymphatic node histology including adenocarcinoma, squamous cell, adenosquamous and a mixture of above. By different histological component and cutoff value, the concordances of PD-L1 expression were in 74.1%, 80.0%, 88.9% cases for adenomatous cell component and 90.0%, 80.0%, 85.0% cases for squamous cell component respectively. In addition, the discrepancy of adenocarcinoma histological subtype accounts for the lower concordant rate in adenomatous component.Table: 396OTable 1.1 PD-L1 difference between adenomatous and squamous componentscutoff valuePD-L1 expression in TC in primary tumor siteconcordance (%)adenomatous component PD-L1+ n (%)squamous cell component PD-L1+ n(%)kappa0.0173.632 (44.4)39 (54.2)0.4770.0580.615 (20.8)24 (33.3)0.5270.1087.56 (8.3)11 (15.3)0.407Table 1.2 PD-L1 heterogeneity between adenomatous and squamous components based on tumor cells and TILscutoff valuePD-L1 expression in TC and TILs in primary tumor siteconcordance (%)adenomatous component PD-L1+ n(%)squamous cell component PD-L1+ n(%)kappa0.0169.447(65.3)45(62.5)0.3380.0577.820(27.8)26(36.1)0.4930.1086.17(9.7)11 (15.3)0.370Table 1.3 PD-L1 difference in TC between primary tumor site and lymphatic metastasiscut off valueadenomatous component n = 27squamous cell component n = 20concordanceprimary tumor PD-L1+ n(%)nodal metastasis PD-L1+ n (%)kappaconcordanceprimary tumor PD-L1+ n(%)nodal metastasis PD-L1+ n (%)kappa0.0177.814 (51.9)12 (44.4)0.55790.012 (60.0)12 (60.0)0.7920.0574.19 (33.3)6 (22.2)0.36480.09 (45.0)9 (45.0)0.5960.1088.94 (14.8)3 (11.1)0.50985.05 (25.0)4 (20.0)0.571 Open table in a new tab Conclusions: PD-L1 expression showed a high discrepancy among adenomatous component and squamous cell components. In contrast, PD-L1 was highly consistent between paired histological types of lymph node and the primary lesion, which may suggest that the intrinsic genomic features plays important role in the PDL1 heterogeneously expression. Legal entity responsible for the study: Tongji Pulmonary Hospital, Tongji University Funding: Shanghai Municipal Education Commission Disclosure: All authors have declared no conflicts of interest.

The Heterogeneity of PD-L1 Expression among the Different Histological Components and Metastatic Lymph Nodes in Patients with Resected Lung Adenosquamous Carcinoma

PD-L1 Expression in Non-Small Cell Lung Cancer: Heterogeneity by Pathologic Types, Tissue Sampling and Metastasis.

Clinical Significance of 22C3-PD-L1 IHC Expression in Surgically Resected Non-Small Cell Lung Cancer

Prognostic Value of PD-L1 Expression in Combination with CD8+ TILs Density in Patients with Surgically Resected Non-Small Cell Lung Cancer.

P2.01-052 High PD-L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung

[Comparative Study of PD-L1 Expression in Different Sites of Non-small Cell Lung Cancer]

Adverse Prognostic Value of PD-L1 Expression in Primary Resected Pulmonary Squamous Cell Carcinomas and Paired Mediastinal Lymph Node Metastases

Comparison of 22C3 PD-L1 Expression Between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer

Correlation Between PD-L1 Expression and Clinicopathological Features in Surgically Resected Lung Adenocarcinoma: a Case Series Analysis

Distribution of PD-L1 Expression and Its Relationship with Clinicopathological Variables: an Audit from 1071 Cases of Surgically Resected Non-Small Cell Lung Cancer.

PD‐L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system

Expression Changes in Programmed Death Ligand 1 from Precancerous Lesions to Invasive Adenocarcinoma in Subcentimeter Pulmonary Nodules: A Large Study of 2022 Cases in China

Characterization of PD-L1 Protein Expression and CD8+ Tumor-Infiltrating Lymphocyte Density, and Their Associations with Clinical Outcome in Small-Cell Lung Cancer.

Expression of Programmed Death Ligand 1 in Lung Adenocarcinoma and Its Significance

Prognostic Value of PD-L1 Expression in Resected Lung Adenocarcinoma and Potential Molecular Mechanisms

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China

P2.01-050 Clinicopathological Characteristics of PD-L1 Expression in Lung Adenocarcinoma: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy

Relationship Between PD-L1 Expression and Molecular Aberrances in Lung Adenocarcinoma with Solid Components

High Expression of PD-L1 Mainly Occurs in Non-Small Cell Lung Cancer Patients with Squamous Cell Carcinoma or Poor Differentiation

Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.